Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Press Releases

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Subscribe to email alert

Navigation

Contact Us